RedHill Biopharma (NASDAQ:RDHL) Stock Price Crosses Below Two Hundred Day Moving Average – Should You Sell?

RedHill Biopharma Ltd. (NASDAQ:RDHL)’s stock price passed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $111.65 and traded as low as $7.12. RedHill Biopharma shares last traded at $7.14, with a volume of 11,278 shares changing hands.

Analyst Ratings Changes

Separately, StockNews.com began coverage on shares of RedHill Biopharma in a research report on Saturday, August 24th. They issued a “hold” rating on the stock.

RedHill Biopharma Stock Performance

The company’s 50 day moving average is $7.84 and its 200 day moving average is $111.65.

About RedHill Biopharma

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex.